Kolexia
Chantepie Sylvain Hématologie
Chantepie Sylvain
Hématologie
Hôpital Côte de Nacre
Caen, France
237 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Lymphomes Maladie du greffon contre l'hôte Leucémie-lymphome lymphoblastique à précurseurs B et T Tumeurs hématologiques Leucémie lymphoïde Syndromes myélodysplasiques

Collaborateurs

Voir plus
Chevallier Patrice
Chevallier Patrice
Hôpital Hôtel-Dieu Nantes, Nantes, France
Turlure Pascal
Turlure Pascal
Hôpital Dupuytren, Limoges, France
Dombret Herve
Dombret Herve
Hôpital Saint-Louis, Paris, France
Yakoub-Agha Ibrahim
Yakoub-Agha Ibrahim
Centre Hospitalier de Lille, Lille, France

Industries

Voir plus
Servier
6 collaboration(s)
Dernière en 2023
Pfizer
6 collaboration(s)
Dernière en 2023
MSD
4 collaboration(s)
Dernière en 2023
Abbvie
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood   07 mars 2024
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML: Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Essai Clinique (Syros Pharmaceuticals)   21 février 2024
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Blood cancer journal   19 février 2024
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation: A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Essai Clinique (Celgene)   08 février 2024
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.
Journal of hematology & oncology   07 janvier 2024
Empirical Versus Preemptive Antifungal Therapy: Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   08 décembre 2023
Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Transplantation and cellular therapy   23 novembre 2023
HAPLO-EMPTY: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression: a Nationwide Phase II Study
Essai Clinique (Assistance publique – Hôpitaux de Paris)   21 novembre 2023
FLUCLORIC: Randomized Multicentric Phase III Study Comparing the Efficacy of 2 Reduced Intensity Conditioning Regimens (Clofarabine/Busulfan vs Fludarabine/Busulfan) in Adults With AML and Eligible to Allogeneic Stem Cell Transplantation
Essai Clinique (CHU Nantes)   13 novembre 2023